Product Images Memantine Hydrochloride
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 11 images provide visual information about the product associated with Memantine Hydrochloride NDC 43353-165 by Aphena Pharma Solutions - Tennessee, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Bottle Label 10mg - 43353 165
Aphena Pharma Solutions - TN - Aphena
Figure 1 - memantine fig1
The text describes a figure showing the time course of the change from baseline in ADCS-ADL score for patients who completed 28 weeks of treatment with an unidentified drug (possibly Memantine). The figure shows a mean (+SEM) change in the score, with some patients experiencing clinical improvement and others experiencing clinical decline. There is no further information available.*
Figure 2 - memantine fig2
This is a graph (Figure 2) depicting the cumulative percentage of patients who completed 28 weeks of double-blind treatment and their specified changes from baseline in ADCS-ADL scores. The vertical axis shows percentages from 0 to 100, and the horizontal axis shows scores ranging from -10 to 50.*
Figure 4 - memantine fig4
The text describes a graph or chart showing the cumulative percentage of patients completing 28 weeks of double-blind treatment and their specified changes from baseline in SIB scores. The text also includes references to the placebo and Memartino hydrochloride.*
Figure 6 - memantine fig6
Figure 7 - memantine fig7
Not available.*
Figure 8 - memantine fig8
Figure 3 - memantine figure3
This is a medical chart showing the time course of changes in SIB (Severe Impairment Battery) score for patients who completed 28 weeks of treatment. The chart includes data for a drug called Memantine hydrochloride. There is no additional information available.*
Figure 5 - memantine figure5
The text describes a figure labeled "Figure 5," which displays a graph of the change in ADCS-ADL score for patients who completed 24 weeks of treatment. The graph shows the mean and SEM change from baseline at 0, 2, 4, and 8 months of treatment. This suggests that the figure is likely part of a research study or clinical trial evaluating a treatment for a condition that impacts ADCS-ADL score.*
Structure - memantine structure
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.